Year |
Citation |
Score |
2023 |
Kieliszek AM, Mobilio D, Upreti D, Bloemberg D, Escudero L, Kwiecien JM, Alizada Z, Zhai K, Ang P, Chafe SC, Vora P, Venugopal C, Singh SK. Intratumoral Delivery of Chimeric Antigen Receptor-T Cells Targeting CD133 Effectively Treats Brain Metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37787999 DOI: 10.1158/1078-0432.CCR-23-1735 |
0.379 |
|
2020 |
Upreti D, Bakhshinyan D, Bloemberg D, Vora P, Venugopal C, Singh SK. Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors. Frontiers in Immunology. 11: 599253. PMID 33281826 DOI: 10.3389/fimmu.2020.599253 |
0.309 |
|
2020 |
Vora P, Venugopal C, Salim SK, Tatari N, Bakhshinyan D, Singh M, Seyfrid M, Upreti D, Rentas S, Wong N, Williams R, Qazi MA, Chokshi C, Ding A, Subapanditha M, et al. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. PMID 32464096 DOI: 10.1016/J.Stem.2020.04.008 |
0.4 |
|
2019 |
Vora P, Seyfrid M, Venugopal C, Qazi MA, Salim S, Isserlin R, Subapanditha M, O'Farrell E, Mahendram S, Singh M, Bakhshinyan D, Chokshi C, McFarlane N, Dvorkin-Gheva A, Brown KR, et al. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. Journal of Neuro-Oncology. PMID 31115870 DOI: 10.1007/S11060-019-03192-1 |
0.475 |
|
2019 |
Hu AX, Adams JJ, Vora P, Qazi M, Singh SK, Moffat J, Sidhu SS. EPH Profiling of BTIC Populations in Glioblastoma Multiforme Using CyTOF. Methods in Molecular Biology (Clifton, N.J.). 1869: 155-168. PMID 30324522 DOI: 10.1007/978-1-4939-8805-1_14 |
0.401 |
|
2019 |
Vora P, Venugopal C, Chokshi C, Qazi M, Tatari N, Brown K, Yelle N, Adams J, Tieu D, Seyfrid M, Singh M, Savage N, Subapanditha M, Bakhshinyan D, Kuhlmann L, et al. Abstract 570: A glioblastoma translational pipeline: discovery of novel tumor antigens that drive GBM recurrence Cancer Research. 79: 570-570. DOI: 10.1158/1538-7445.Am2019-570 |
0.416 |
|
2018 |
Bakhshinyan D, Venugopal C, Adile AA, Garg N, Manoranjan B, Hallett R, Wang X, Mahendram S, Vora P, Vijayakumar T, Subapanditha M, Singh M, Kameda-Smith MM, Qazi M, McFarlane N, et al. BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene. PMID 30348991 DOI: 10.1038/S41388-018-0549-9 |
0.418 |
|
2018 |
Singh M, Venugopal C, Tokar T, McFarlane N, Subapanditha MK, Qazi M, Bakhshinyan D, Vora P, Murty N, Jurisica I, Singh SK. Therapeutic targeting of the pre-metastatic stage in human brain metastasis. Cancer Research. PMID 29986997 DOI: 10.1158/0008-5472.Can-18-1022 |
0.436 |
|
2018 |
Qazi MA, Vora P, Venugopal C, Adams J, Singh M, Hu AX, Gorelik M, Subapanditha MK, Savage N, Yang J, Chokshi C, London M, Gont A, Bobrowski D, Grinshtein N, et al. Co-targeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma. Cancer Research. PMID 29945963 DOI: 10.1158/0008-5472.Can-18-0267 |
0.4 |
|
2018 |
Singh M, Venugopal C, Tokar T, McFarlane N, Subhapanditha M, Bakhshinyan D, Qazi M, Vora P, Savage N, Murty NK, Jurisica I, Singh SK. Abstract 44: Characterization and targeting of a temporal micro-metastatic signature in human brain metastases Tumor Biology. DOI: 10.1158/1538-7445.Am2018-44 |
0.356 |
|
2018 |
Chokshi C, Tieu D, Brown K, Venugopal C, Vora P, Chan K, Tong A, Qazi M, Singh M, Savage N, Habsid A, Moffat J, Singh S. Abstract 390: Genome-wide CRISPR screens in brain tumor initiating cells (BTICs) identify potent sensitizers and resistors of conventional chemoradiotherapy Cancer Research. 78: 390-390. DOI: 10.1158/1538-7445.Am2018-390 |
0.382 |
|
2018 |
Vora P, Adams J, Singh M, Venugopal C, Tatari N, Chokshi C, Qazi M, Salim S, Mahendram S, Bakhshinyan D, London M, Savage N, Subapanditha M, McFarlane N, Pan J, et al. Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies Cancer Research. 78: 1763-1763. DOI: 10.1158/1538-7445.Am2018-1763 |
0.425 |
|
2017 |
Singh M, Venugopal C, Tokar T, Brown KR, McFarlane N, Bakhshinyan D, Vijayakumar T, Manoranjan B, Mahendram S, Vora P, Qazi M, Dhillon M, Tong A, Durrer K, Murty N, et al. RNAi screen identifies essential regulators of human brain metastasis-initiating cells. Acta Neuropathologica. PMID 28766011 DOI: 10.1007/S00401-017-1757-Z |
0.433 |
|
2017 |
Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, Singh SK. Intratumoral Heterogeneity: Pathways to Treatment Resistance and Relapse in Human Glioblastoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28407030 DOI: 10.1093/Annonc/Mdx169 |
0.402 |
|
2017 |
Vora P, Chokshi C, Qazi M, Singh M, Venugopal C, Mahendram S, Adams J, Bakhshinyan D, London M, Singh J, Subapanditha M, McFarlane N, Pan J, Bramson J, Sidhu S, et al. Abstract 3758: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma Cancer Research. 77: 3758-3758. DOI: 10.1158/1538-7445.Am2017-3758 |
0.395 |
|
2017 |
Qazi M, Vora P, Chokshi C, Venugopal C, London M, Hu A, Subapandtiha M, Singh M, Adams J, Moffat J, Sidhu S, Singh SK. Abstract 3639: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in human glioblastoma Cancer Research. 77: 3639-3639. DOI: 10.1158/1538-7445.Am2017-3639 |
0.415 |
|
2017 |
Chokshi C, Tieu D, Vora P, Venugopal C, Chan K, Tong A, Brown K, Singh M, Moffat J, Singh S. Stem-42. Genome-Wide Crispr Screens In Brain Tumor Initiating Cells (Btics) Identify Potent Sensitizers Of Conventional Chemoradiotherapy. Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.956 |
0.374 |
|
2017 |
Seyfrid M, Chokshi C, Kuhlmann L, Venugopal C, Vora P, Sinha A, Ignatchenko V, Macklin A, Kislinger T, Singh S. Stem-17. Characterization Of The Cell Surface Proteome In Recurrent Glioblastoma Initiating Cells Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.933 |
0.342 |
|
2017 |
Qazi M, Vora P, Venugopal C, Gorelik M, Singh M, Hu A, Subapanditha M, Chokshi C, Savage N, Yelle N, Adams J, Moffat J, Sidhu S, Singh S. IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC
EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA Neuro-Oncology. 19: vi113-vi113. DOI: 10.1093/Neuonc/Nox168.462 |
0.418 |
|
2017 |
Manoranjan B, Venugopal C, Mahendram S, Subapanditha M, Savage N, Qazi M, Vora P, Moffat J, Doble B, Singh S. CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS Neuro-Oncology. 19: vi54-vi54. DOI: 10.1093/Neuonc/Nox168.216 |
0.391 |
|
2017 |
Singh M, Venugopal C, Tokar T, McFarlane N, Bakhshinyan D, Qazi M, Vora P, Murty N, Jurisica I, Singh S. CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES Neuro-Oncology. 19: vi49-vi49. DOI: 10.1093/Neuonc/Nox168.193 |
0.364 |
|
2017 |
Singh M, Venugopal C, Vora P, Adams J, Pan J, Chokshi C, Murty N, Sidhu S, Moffat J, Singh S. CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.182 |
0.37 |
|
2016 |
Tripathi A, Parikh ZS, Vora P, Frost EE, Pillai PP. pERK1/2 Peripheral Recruitment and Filopodia Protrusion Augment Oligodendrocyte Progenitor Cell Migration: Combined Effects of PDGF-A and Fibronectin. Cellular and Molecular Neurobiology. PMID 26993510 DOI: 10.1007/S10571-016-0359-Y |
0.355 |
|
2016 |
Vora P, Qazi M, Chokshi C, Venugopal C, London M, Hu A, McFarlane N, Subapanditha M, Singh M, Mahendram S, Adams J, Moffat J, Sidhu S, Singh S. Abstract B092: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B092 |
0.455 |
|
2016 |
Vora P, Chokshi C, Qazi M, Venugopal C, Mahendram S, Singh M, Adams J, Bakhshinyan D, London M, Subapanditha M, McFarlane N, Pan J, Bramson J, Moffat J, Sidhu S, et al. Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B079 |
0.388 |
|
2016 |
Vora P, Qazi M, Venugopal C, Subapanditha M, Mahendram S, Chokshi C, Singh M, Bakhshinyan D, McFarlane N, Singh S. Abstract 2512: Bmi1 identifies treatment-refractory stem cells in human glioblastoma Cancer Research. 76: 2512-2512. DOI: 10.1158/1538-7445.Am2016-2512 |
0.461 |
|
2016 |
Vora P, Venugopal C, Mahendram S, Chokshi C, Qazi M, Subapanditha M, Singh M, Bakhshinyan D, Bezverbnaya K, Adams J, McFarlane N, Sidhu S, Moffat J, Bramson J, Singh S. Abstract 2300: Human CD133-specific chimeric antigen receptor (CAR) modified T cells target patient-derived glioblastoma brain tumors Cancer Research. 76: 2300-2300. DOI: 10.1158/1538-7445.Am2016-2300 |
0.381 |
|
2016 |
Vora P, Venugopal C, Adams J, Pan J, Chokshi C, Qazi M, Subapanditha M, Singh M, Bakhshinyan D, Bezverbnaya K, McFarlane N, Bramson J, Sidhu S, Moffat J, Singh S. Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells Cancer Research. 76: 1481-1481. DOI: 10.1158/1538-7445.Am2016-1481 |
0.401 |
|
2016 |
Singh M, Venugopal C, Tokar T, Brown K, McFarlane N, Bakhshinyan D, Vora P, Qazi M, Mahendram S, Vijaykumar T, Manoranjan B, Tong A, Durrer K, Murty N, Hallet R, et al. TMOD-23. DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO- BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS Neuro-Oncology. 18: vi211-vi212. DOI: 10.1093/Neuonc/Now212.893 |
0.385 |
|
2016 |
Qazi M, Vora P, Venugopal C, Bakhshinyan D, Nixon A, Brown K, Subapanditha M, Chokshi C, Murty N, Moffat J, Singh S. TMOD-02. Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.872 |
0.336 |
|
2016 |
Vora P, Chokshi C, Qazi M, Venugopal C, Mahendram S, Singh M, Adams J, London M, Bakhshinyan D, Subapanditha M, McFarlane N, Pan J, Bramson J, Moffat J, Sidhu S, et al. IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.409 |
0.328 |
|
2016 |
Vora P, Venugopal C, Choksi C, Qazi M, Adams J, London M, Subapanditha M, Singh M, Bakshinyan D, Sidhu S, Moffat J, Singh S. PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells Canadian Journal of Neurological Sciences. 43. DOI: 10.1017/Cjn.2016.367 |
0.352 |
|
2016 |
Vora P, Qazi M, Venugopal C, Subapanditha M, Mahendram S, Chokshi C, Singh M, Bakhshinyan D, McFarlane N, Singh S. PS2 - 171 Bmi1 Identifies Treatment-Refractory Stem Cells in Human Glioblastoma Canadian Journal of Neurological Sciences. 43. DOI: 10.1017/Cjn.2016.366 |
0.35 |
|
2016 |
Bakhshinyan D, Vijayakumar T, Manoranjan B, McFarlane N, Venugopal C, Singh M, Qazi M, Vora P, Singh S. PS1 - 169 Discovering the Treatment Refractory BTIC Population in Group 3 Medulloblastoma through Therapy Adapted Patient-Derived Human Mouse Xenograft (PDX) Model Canadian Journal of Neurological Sciences. 43. DOI: 10.1017/Cjn.2016.357 |
0.307 |
|
2016 |
Singh M, Venugopal C, Tokar T, Brown KR, McFarlane N, Bakhshinyan D, Vijayakumar T, Manoranjan B, Mahendram S, Vora P, Qazi M, Dhillon M, Tong A, Durrer K, Murty N, et al. OS2 - 166 A Novel Model of Human Lung-to-Brain Metastasis and its Application to the Identification of Essential Metastatic Regulatory Genes Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 43: S2-S2. DOI: 10.1017/Cjn.2016.333 |
0.43 |
|
2016 |
Qazi MA, Vora P, Venugopal C, Bakhshinyan D, Nixon A, McFarlane N, Subapanditha MK, Murty NK, Hallett RM, Moffat J, Singh SK. Modelling Therapy Resistance for the Identification of Treatment-Refractory Cell Population(s) in Human Glioblastoma Canadian Journal of Neurological Sciences. 43. DOI: 10.1017/Cjn.2016.330 |
0.329 |
|
2015 |
Qazi MA, Vora P, Venugopal C, McFarlane N, Subapanditha MK, Murty NK, Hassell JA, Hallett RM, Singh SK. A novel stem cell culture model of recurrent glioblastoma. Journal of Neuro-Oncology. PMID 26498281 DOI: 10.1007/S11060-015-1951-6 |
0.468 |
|
2015 |
Singh M, Garg N, Venugopal C, Hallett R, Tokar T, McFarlane N, Mahendram S, Bakhshinyan D, Manoranjan B, Vora P, Qazi M, Arpin CC, Page B, Haftchenary S, Rosa DA, et al. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget. PMID 26314961 DOI: 10.18632/Oncotarget.4742 |
0.391 |
|
2015 |
Vora P, Venugopal C, McFarlane N, Singh SK. Culture and Isolation of Brain Tumor Initiating Cells. Current Protocols in Stem Cell Biology. 34: 3.3.1-3.3.13. PMID 26237571 DOI: 10.1002/9780470151808.sc0303s34 |
0.344 |
|
2015 |
Singh SK, Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi M, McFarlane N, Subapanditha M, Nolte S, Singh M, Bakhshinyan D, Garg N, Vijayakumar T, Lach B, et al. Pyrvinium targets CD133 in human glioblastoma brain tumor-initiating cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26152745 DOI: 10.1158/1078-0432.Ccr-14-3147 |
0.433 |
|
2015 |
Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi M, McFarlane N, Subapanditha M, Nolte S, Singh M, Bakhshinyan D, Garg N, Boleslaw L, John P, Reddy K, et al. STEM-23PYRVINIUM TARGETS CD133 IN HUMAN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS Neuro-Oncology. 17: v213.1-v213. DOI: 10.1093/Neuonc/Nov234.23 |
0.451 |
|
2015 |
Vora P, Qazi M, Venugopal C, Subapanditha M, Bakhshinyan D, Mahendram S, McFarlane N, Singh S. ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov204.92 |
0.449 |
|
2014 |
Qazi M, Mann A, van Ommeren R, Venugopal C, McFarlane N, Vora P, Singh SK. Generation of murine xenograft models of brain tumors from primary human tissue for in vivo analysis of the brain tumor-initiating cell. Methods in Molecular Biology (Clifton, N.J.). 1210: 37-49. PMID 25173159 DOI: 10.1007/978-1-4939-1435-7_4 |
0.413 |
|
2014 |
Vora P, Venugopal C, Qazi M, Mahendram S, McFarlane N, Singh S. SC-33POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou275.32 |
0.434 |
|
2014 |
Qazi M, Vora P, Venugopal C, McFarlane N, Hallett R, Singh S. Rm-06In Vitro Clonal Evolution Of Glioblastoma (Gbm) Brain Tumour Initiating Cells (Btic) To Model Tumour Recurrence Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou273.6 |
0.472 |
|
2014 |
Singh SK, Manoranjan B, Venugopal C, Vora P, McFarlane N, Garg N, Singh M, Mann A, Bakhshinyan D, Mahendran S, Dunn S. Sox2 Identifies The Treatment-Refractory Stem Cell Population In Group 2 Medulloblastoma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.16 |
0.458 |
|
2012 |
Vora P, Pillai P, Mustapha J, Kowal C, Shaffer S, Bose R, Namaka M, Frost EE. CXCL1 regulation of oligodendrocyte progenitor cell migration is independent of calcium signaling. Experimental Neurology. 236: 259-67. PMID 22554866 DOI: 10.1016/J.Expneurol.2012.04.012 |
0.651 |
|
2012 |
Zhu W, Frost EE, Begum F, Vora P, Au K, Gong Y, Macneil B, Pillai P, Namaka M. The role of dorsal root ganglia activation and brain-derived neurotrophic factor in multiple sclerosis Journal of Cellular and Molecular Medicine. 16: 1856-1865. PMID 22050733 DOI: 10.1111/J.1582-4934.2011.01481.X |
0.632 |
|
2011 |
Vora P, Pillai PP, Zhu W, Mustapha J, Namaka MP, Frost EE. Differential effects of growth factors on oligodendrocyte progenitor migration. European Journal of Cell Biology. 90: 649-56. PMID 21616555 DOI: 10.1016/J.Ejcb.2011.03.006 |
0.384 |
|
2010 |
Vora P, Mina R, Namaka M, Frost EE. A novel transcriptional regulator of myelin gene expression: Implications for neurodevelopmental disorders Neuroreport. 21: 917-921. PMID 20697302 DOI: 10.1097/Wnr.0B013E32833Da500 |
0.322 |
|
Show low-probability matches. |